Skip to content

Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy

Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy to Prevent Postoperative Pancreatic Fistula

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03419676
Enrollment
64
Registered
2018-02-05
Start date
2018-05-01
Completion date
2022-02-10
Last updated
2022-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Fistula

Keywords

Pancreatoduodenectomy, Postoperative pancreatic fistula, Sealant, Hemopatch

Brief summary

The objective of this study is to determine the effect of the sealant patch Hemopatch, compared to current practice without any sealant, on the decrease of the postoperative pancreatic fistula on patients undergoing pancreatoduodenectomy for benign or malignant tumors or other benign process.

Detailed description

Pancreaticoduodenectomy (PD) is the most common surgical procedure to treat pancreatic tumors in the head of the pancreas and periampullary region, as well as benign processes such as chronic pancreatitis. Recent advances in surgical techniques and perioperative treatments have reduced perioperative mortality below 10% in high volume centers. However, PD is associated with considerable morbidity (40-58.5%) like postoperative pancreatic fistula, delayed gastric emptying, biliary fistula, postoperative hemorrhage, and pulmonary complications. Several surgical techniques and perioperative care have been described to prevent or reduce the incidence of pancreatic fistula after PD, including reconstruction of the digestive tract with pancreaticogastrostomy, duc-to-mucosa reconstruction or pancreaticojejunostomy by intussusception, use of somatostatin and prophylactic analogues, the use of stents in the main pancreatic duct, and use of different sealants. Although perioperative morbidity and mortality associated with PD have improved significantly over the years, even in high-volume centers, the incidence of postoperative fistula remains at 9.9-28.5%. Therefore, the ideal pancreatic reconstruction technique that prevents fistula is not yet available. The use of sealants has been one of the approaches taken to try to reduce the rate of fistulas. Some uncontrolled or non-randomized studies have shown that the use of fibrin glue-based adhesives in combinations with felting patches can lead to a B / C grade fistula rate of 0-10%. Only 2 randomized clinical trials have been performed with fibrin glue, with opposite results in terms of significant reduction of pancreatic fistula. Hemopatch is a patch consisting of a soft, thin and flexible pad of collagen derived from the bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate). It is intended to be a surgical sealant for procedures in which control of leakage by conventional surgical techniques is ineffective or impractical, making it a plausible option to use during PD in order to decrease postoperative pancreatic fistula.

Interventions

DEVICEHemopatch

Collagen patch derived from bovine dermis, coated with NHS-PEG, applied covering the pancreaticojejunostomy after pancreatoduodenectomy once the anastomosis is completed.

Sponsors

Aragon Health Science Institute
CollaboratorOTHER_GOV
Hospital Miguel Servet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

All patient data are anonymous. Each patient who meets the selection criteria and has signed the informed consent will be entered into a database and identified by a number (from 1 to 64). The list of patient identification numbers will be in the hands of the principal investigator. After carrying out the surgery, the patient number is entered into an online computerized randomization tool (Randomizer for clinical trials), https://www.meduniwien.ac.at/randomizer. It is a tool of the University of Vienna in Austria, where it is registered in a study, which allows, once the patient number is entered, the randomization of the same, obtaining one of the two methods to compare (32 patients in each study group): 1. Basic treatment: duct-to-mucosa pancreaticojejunostomy WITHOUT Hemopatch reinforcement. 2. The same, but reinforced WITH Hemopatch. Once the treatment to be performed is obtained, surgery will be carried out according to the treatment obtained in the randomization.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients scheduled for pancreatoduodenectomy by open approach, depending on the diagnosis/nature of the tumor. * ASA score \< 4. * Male and female patients ≥ 18 and ≤ 80 years of age. * With the consent form signed.

Exclusion criteria

* Patients scheduled for pancreatoduodenectomy by open approach, depending on the diagnosis/nature of the tumor. * ASA score \< 4. * Male and female patients ≥ 18 and ≤ 80 years of age. * With the consent form signed.

Design outcomes

Primary

MeasureTime frameDescription
Postoperative type B and C pancreatic fistulaUp to 3 monthsPostoperative type B and C pancreatic fistula rate defined according to the International Study Group of Pancreatic Fistula criteria, measured by amylases and/or lipases levels in the perianastomotic drainage

Secondary

MeasureTime frameDescription
Stay in intensive care unitUp to 3 monthsDays of duration
Total postoperative fistula (including type A, B, and C)Up to 3 monthsPercentage of patients
Reoperations including interventional radiologyUp to 3 monthsPercentage of patients
Delayed gastric emptyingUp to 3 monthsPercentage of patients
Hospital stayUp to 3 monthsDays of duration
HemorrhageUp to 3 monthsPercentage of patients
Deep organ space complicationsUp to 3 monthsDeep organ space complications
Death, irrespective of causeUp to 3 monthsDeath
Overall complications (according to Clavien-Dindo classification)Up to 3 monthsPercentage of patients
Biliary fistulaUp to 3 monthsPercentage of patients

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026